(Q39829510)

15 September 2017

Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer (English)

1 reference

15 September 2017

Satoshi Anai

1

1 reference

15 September 2017

Noboru Sakamoto

2

1 reference

15 September 2017

Yoshihisa Sakai

3

1 reference

15 September 2017

Motoyoshi Tanaka

4

1 reference

15 September 2017

Stacy Porvasnik

5

1 reference

15 September 2017

Cydney Urbanek

6

1 reference

15 September 2017

Wengang Cao

7

1 reference

15 September 2017

Steve Goodison

8

1 reference

15 September 2017

Charles J Rosser

9

1 reference

15 September 2017

language of work or name

1 reference

3 July 2009

1 reference

15 September 2017

1 reference

15 September 2017

29

1 reference

15 September 2017

421-429

1 reference

15 September 2017

4

1 reference

15 September 2017

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.009

Molecular markers and mortality in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.009

Combined analysis with Bcl-2 and P53 immunostaining predicts poorer prognosis in prostatic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.009

Regulation of Bcl-2 proteins and of the permeability of the outer mitochondrial membrane.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.009

Unknotting the roles of Bcl-2 and Bcl-xL in cell death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.009

Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.009

Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.009

Angiogenic potential of prostate carcinoma cells overexpressing bcl-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.009

Irradiation of human prostate cancer cells increases uptake of antisense oligodeoxynucleotide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.009

Antitumor Efficacy of bcl-2 and c-myc Antisense Oligonucleotides in Combination with Cisplatin in Human Melanoma Xenografts: Relevance of the Administration Sequence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.009

z-Guggulsterone, a constituent of Ayurvedic medicinal plant Commiphora mukul, inhibits angiogenesis in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.009

Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.009

Adenoviral-mediated PTEN transgene expression sensitizes Bcl-2-expressing prostate cancer cells to radiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.009

Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.009

Modulation of the organ microenvironment for treatment of cancer metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.009

Angiogenesis inhibition: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.009

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.009

Vascular endothelial growth factor is a secreted angiogenic mitogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.009

Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.009

The regulation of blood vessel growth by vascular endothelial growth factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.009

Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.009

ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.009

Biomarker expression patterns that correlate with high grade features in treatment naive, organ-confined prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.009

p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.009

10.1016/J.UROLONC.2009.04.009

7 January 2021

Identifiers

DOI

1 reference

release_3jll6etltba7hpupwuz6qcuew4

15 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3jll6etltba7hpupwuz6qcuew4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference